Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dimitrios Arhontoulis"'
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Autor:
Vijay G. Bhoj, Lucy Li, Kalpana Parvathaneni, Zheng Zhang, Stephen Kacir, Dimitrios Arhontoulis, Kenneth Zhou, Bevin McGettigan-Croce, Selene Nunez-Cruz, Gayathri Gulendran, Alina C. Boesteanu, Laura Johnson, Michael D. Feldman, Enrico Radaelli, Keith Mansfield, MacLean Nasrallah, Rebecca S. Goydel, Haiyong Peng, Christoph Rader, Michael C. Milone, Don L. Siegel
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 387-398 (2021)
Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell immunotherapy using chimeric antigen receptor (CAR)-modifi
Externí odkaz:
https://doaj.org/article/21295495ac0b4d158ff8bf09829bb9f3
Autor:
Dimitrios Arhontoulis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d206663422094e49bdade812940c08a3
Autor:
Dimitrios Arhontoulis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/063df4eaf0124d13b215c515f2320f41
Autor:
Guillermo Rangel Rivera, Guillermo Rangel RIvera, Connor Dwyer, Dimitrios Arhontoulis, Hannah Knochelmann, Aubrey Smith, Megan Wyatt, Amalia Rivera Reyes, Chrystal Paulos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Durable responses have been observed with adoptive T cell therapy (ACT) in some patients. However, current protocols used to expand T cells often exhibit suboptimal tumor control. Failure in these therapies has been attributed to premature
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Autor:
Selene Nunez-Cruz, Michael Feldman, Kenneth Zhou, Christoph Rader, Haiyong Peng, Stephen Kacir, Keith Mansfield, Alina C. Boesteanu, Zheng Zhang, Enrico Radaelli, MacLean Nasrallah, Bevin McGettigan-Croce, Rebecca S. Goydel, Vijay Bhoj, Don L. Siegel, Michael C. Milone, Kalpana Parvathaneni, Gayathri Gulendran, Dimitrios Arhontoulis, Lucy Z. Li, Laura A. Johnson
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 387-398 (2021)
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 387-398 (2021)
Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell immunotherapy using chimeric antigen receptor (CAR)-modifi
Autor:
Vijay Bhoj, Christoph T. Ellebrecht, Gerald Wertheim, Michael C. Milone, Dimitrios Arhontoulis, Wei-Ting Hwang, S. Grupp, Shannon L. Maude, Adam Bagg, Simon F. Lacey, Amrom E. Obstfeld, Michael Feldman, Mariusz A. Wasik, Farzana Nazimuddin, J. Joseph Melenhorst, Colleen Callahan, David L. Porter, Stephen J. Schuster, James Capobianchi, Carl H. June
Publikováno v:
Blood. 128(3)
The mechanisms underlying the maintenance of long-lasting humoral immunity are not well understood. Studies in mice indicate that plasma cells (PCs) can survive up to a lifetime, even in the absence of regeneration by B cells, implying the presence o
Autor:
Selene Nunez-Cruz, Michael Feldman, Keith Mansfield, Vijay Bhoj, Haiyong Peng, Christoph Rader, Kenneth Zhou, Michael C. Milone, Don L. Siegel, Dimitrios Arhontoulis
Publikováno v:
Cancer Research. 76:2295-2295
Metastatic medullary thyroid cancer (MTC) is a rare, but often aggressive, thyroid malignancy with a 5-year survival rate of 28% and few effective therapeutic options. Adoptive T-cell immunotherapy using chimeric antigen receptor (CAR)-modified T cel